JP2004168732A - Active oxygen-scavenging agent, inhibitor for synthesis promotion/decomposition of hyaluronic acid, and aquaporin synthesis promotor - Google Patents

Active oxygen-scavenging agent, inhibitor for synthesis promotion/decomposition of hyaluronic acid, and aquaporin synthesis promotor Download PDF

Info

Publication number
JP2004168732A
JP2004168732A JP2002338871A JP2002338871A JP2004168732A JP 2004168732 A JP2004168732 A JP 2004168732A JP 2002338871 A JP2002338871 A JP 2002338871A JP 2002338871 A JP2002338871 A JP 2002338871A JP 2004168732 A JP2004168732 A JP 2004168732A
Authority
JP
Japan
Prior art keywords
skin
hyaluronic acid
synthesis
active oxygen
aquaporin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002338871A
Other languages
Japanese (ja)
Inventor
Yoshinobu Sugiyama
義宣 杉山
Hiroyuki Yoshida
浩之 吉田
Sayuri Yamaguchi
さゆり 山口
Kohei Yamazaki
恒平 山崎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kanebo Ltd
Original Assignee
Kanebo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanebo Ltd filed Critical Kanebo Ltd
Priority to JP2002338871A priority Critical patent/JP2004168732A/en
Publication of JP2004168732A publication Critical patent/JP2004168732A/en
Pending legal-status Critical Current

Links

Images

Landscapes

  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To obtain an active oxygen scavenging agent causing excellent moisture retention to the skin, chapped skin-improving, and having aging-preventing and bleaching effects on the skin by scavenging active oxygen, inhibiting the production of lipoperoxides in the skin, promoting hyaluronic acid producing ability of a skin cell and inhibiting the decomposition ability and further promoting aquaporin synthesis of a skin cell, and to obtain an inhibitor for synthesis promotion/decomposition of hyaluronic acid and an aquaporin synthesis promotor. <P>SOLUTION: The active oxygen scavenging agent, the inhibitor for synthesis promotor and decomposition of the hyaluronic acid and the aquaporin synthesis promotor comprise each an extract obtained from a plant of the family Tropaeolaceae. <P>COPYRIGHT: (C)2004,JPO

Description

【0001】
【発明の属する技術分野】
本発明は、活性酸素消去剤、ヒアルロン酸合成促進剤、ヒアルロン酸分解抑制剤及びアクアポリン合成促進剤に関し、更に詳しくは、活性酸素を消去し皮膚中での過酸化脂質の生成を抑制し、皮膚細胞のヒアルロン酸産生能を促進させるとともに分解能を抑制し、さらには皮膚細胞のアクアポリン合成を促進することにより、皮膚に対する優れた保湿性、荒れ肌改善、老化防止および美白効果が期待される活性酸素消去剤、ヒアルロン酸合成促進剤及び分解抑制剤並びにアクアポリン合成促進剤に関する。
【0002】
【従来の技術】
老化した皮膚では過酸化脂質が増大し、柔軟性、弾力性を失い、皮膚のしわが増大し、乾燥して滑らかさのない荒れ肌症状が認められる。これらの皮膚症状が現れる原因物質の一つとして、大気中の酸素が紫外線や酵素等の影響を受けて生成するいわゆる活性酸素が考えられている。このような活性酸素には、スーパーオキシド、ヒドロキシラジカル、一重項酸素、過酸化水素等がある。この活性酸素は脂肪酸を酸化し、過酸化物を生成させる。その上、生成した過酸化物と活性酸素は、生体に対してコラーゲン線維の架橋、ヒアルロン酸の断片化、DNA螺旋の部分開裂、連鎖的ラジカルの発生による組織の損傷等の悪影響を及ぼし、その結果として、皮膚のしわや弾力消失、脱毛といった生体の老化を促進するといわれている。
【0003】
一方、日焼けによる色黒、しみ、そばかす等の皮膚への色素沈着は、黒褐色無定型の色素であるメラニンの生成によって生じるものと考えられている。メラニンは、表皮基底層に存在するメラノサイトと呼ばれる色素細胞内のメラノソームにおいて、チロシナーゼによってチロシンからドーパ、ドーパからドーパキノンに変換された後、各種メラニン中間代謝産物を経て、酸化重合して生成される。紫外線により生成された活性酸素は、この系の酸化反応を活性化するため、メラニンが過剰に生成され、皮膚への色素沈着を促進するといわれている。
【0004】
したがって、活性酸素を消去することは、皮膚の老化及び色素沈着を改善あるいは予防する点で皮膚にとって非常に重要なことであり、老化防止皮膚化粧料に求められる重要な要素である。
【0005】
そのため、従来、生体内に発生した活性酸素を消去する作用のある物質の探索が広く行われてきた。この様な作用を有する物質として、従来用いられてきたものとしては、天然物由来のものでは、脂溶性のトコフェロール(ビタミンE)、水溶性のアスコルビン酸(ビタミンC)等が挙げられ、合成化合物では、BHT(ブチルヒドロキシトルエン)、BHA(ブチルヒドロキシアニソール)等が挙げられる。しかし、これらの物質は活性酸素消去作用が十分ではなく、合成化合物において、BHAは発癌性を有する疑いが一部持たれており、いずれも活性酸素消去剤としては実用的とは言い難かった。したがって、生体内に発生する活性酸素を消去する作用を十分に有し、安全性が高く、皮膚等への適用性の良好な活性酸素消去剤が強く望まれている。
【0006】
皮膚の老化防止という側面では、皮膚中のヒアルロン産量を高めることも重要である。ヒアルロン酸は、細胞間隙への水分の保持、組織内にジェリー状のマトリックスを形成することに基づく細胞の保持、組織の潤滑性と柔軟性の保持、機械的障害などの外力への抵抗、および、細菌感染の防止など多くの機能を有している(例えば、非特許文献1)。
【0007】
皮膚のヒアルロン酸は、齢をとるにつれて減少し、その結果、小ジワやかさつきなどの老化をもたらすといわれている。このような老化した皮膚の改善剤として、コラーゲンやヒアルロン酸を配合した化粧料が数多く提案されているが、表面の保湿効果が改善されるだけであり、本質的に老化肌を改善するものではない。したがって、皮膚細胞のヒアルロン酸産性能を高め分解能を抑制することが皮膚老化の防止に有効である。
【0008】
これまでに述べた皮膚の活性酸素消去やヒアルロン酸を高めることが皮膚に対して優れた効果を示すことに加え、最近の研究により皮膚細胞に存在するアクアポリンが重要な皮膚生理機能を担うことが明らかとなった。
【0009】
アクアポリン(Aquaporin:以下、AQPと略記する)は、水チャンネルとも呼ばれ、水を選択的に透過させる膜たんぱく質として知られている。これまでにヒトでは11種類のAQP遺伝子(AQP0〜AQP10)が発見され、このうちAQP3、AQP7、AQP9は水だけでなくグリセロールや尿素など非イオン性小分子も透過させる。また、ヒト組織でのAQPの発現分布をみると、ほとんどの臓器に複数のAQPが存在していることが明らかとなっている。
【0010】
表皮でのAQPの発現については、本発明者らの最近の研究により、培養ヒトケラチノサイトおよびモデル皮膚表皮でのAQP3、AQP5、AQP9遺伝子の発現が報告されている。このうち培養ヒトケラチノサイトでのAQP3の発現は高浸透圧ストレスにより増加することから、AQP3はケラチノサイトの水環境を制御する一つの重要な因子と考えられる(非特許文献2参照)。また、AQP3遺伝子欠損マウスの皮膚では、角層水分量、皮膚粘弾性、バリアー回復の低下が認められ、AQP3が皮膚物性ならびに皮膚生理機能に深く関与していることが示された(非特許文献3参照)。したがって、アクアポリンの産生促進は、皮膚の乾燥を抑え、はりを整え、バリアー機能を強化すると期待できる。しかしながら、アクアポリン合成促進作用を十分に有し、安全性が高く、皮膚等への適用性の良好なアクアポリン合成促進剤及び皮膚化粧料は知られていない。
【0011】
【非特許文献1】
「BIO INDUSTRY」8巻、1991年、346頁
【非特許文献2】
「Biochimica et Biophysica Acta」1522巻、2001年、82−88頁)
【非特許文献3】
「Journal of Dermatological Science」29巻、143頁
【0012】
【発明が解決しようとする課題】
斯かる状況下、本発明の目的は、活性酸素を消去し皮膚中での過酸化脂質の生成を抑制し、皮膚細胞のヒアルロン酸産生能を促進させるとともに分解能を抑制し、さらには皮膚細胞のアクアポリン合成を促進することにより、皮膚に対する優れた保湿性、荒れ肌改善、老化防止および美白効果を有する活性酸素消去剤、ヒアルロン酸合成促進・分解抑制剤およびアクアポリン合成促進剤を提供することにある。
【0013】
【課題を解決するための手段】
本発明者等は上記の事情に鑑み、鋭意研究した結果、ノウゼンハレン科植物より得られる抽出物が優れた活性酸素消去効果、ヒアルロン酸合成促進・分解抑制効果およびアクアポリン合成促進効果を有し、皮膚の乾燥、荒れ肌、老化および色素沈着を有効に改善あるいは予防することを見出し、本発明を完成するに至った。
【0014】
すなわち、本発明は、ノウゼンハレン科植物より得られる抽出物を含有することを特徴とする活性酸素消去剤、ヒアルロン酸合成促進及び分解抑制剤並びにアクアポリン合成促進剤にある。
【0015】
【発明の実施の形態】
以下、本発明の実施の形態について詳述する。
【0016】
本発明に用いられるノウゼンハレン科植物は、ほふく性の茎をもつ多肉草本であり、原産地をメキシコからパタゴニア地方までの中央・南アフリカの限られた地域としている。観賞用として最も有名なのがノウゼンハレン(Tropaeolum majus)であり、キンレンカ(金蓮花)とも呼ばれ花壇や鉢植えで栽培される。また、未熟な種子は酢漬けにされてケーパーの代わりに食されることもある。
【0017】
本発明のノウゼンハレン科植物抽出物を得るための抽出溶媒としては、水、メタノール、エタノール、イソプロピルアルコール等のアルコール類、エチレングリコール、プロピレングリコール、1,3−ブチレングリコール等の多価アルコール類、アセトン等のケトン類、酢酸エチル等のエステル類、ジエチルエーテル等のエーテル類、及びベンゼン等の芳香族化合物類の、一種又は二種以上の混合物から選択することができる。
【0018】
ノウゼンハレン科植物抽出物は、抽出溶媒溶液のままでも良いし、常法により乾固、濃縮して用いても良い。また、ろ過や、再抽出等を行っても良い。
【0019】
本発明の活性酸素消去剤、ヒアルロン酸合成促進・分解抑制剤およびアクアポリン合成促進剤は、剤型的には例えば軟膏類、ローション類、乳液類、クリーム類、パック類、粉末類、顆粒類等の任意の剤型とすることができ、例えば使用形態として皮膚化粧料が挙げられる。皮膚化粧料の基剤としては、公知の外用基剤で良く、特に限定されない。そして適用する皮膚としては頭皮を含む人体上の皮膚全てに利用が期待できる。
【0020】
本発明のノウゼンハレン科植物抽出物の活性酸素消去剤、ヒアルロン酸合成促進・分解抑制剤およびアクアポリン合成促進剤への配合量は、使用する系によって様々で、一概には言えないが、全量に対して、乾物換算で、0.00001〜10.0質量%(以下、特に断りなければ、%で記する)であると本発明の活性酸素消去効果、ヒアルロン酸合成促進・分解抑制効果、アクアポリン合成促進効果を得るために好ましく、しかも使用時の感触が良好で、また個々の剤型を安定に保つことができる。0.00001%未満では、効果が十分に発揮されない場合があり、一方、10.0%を超えて配合しても配合量に見合った効果が得られない場合がある。
【0021】
本発明の活性酸素消去剤、ヒアルロン酸合成促進・分解抑制剤およびアクアポリン合成促進剤には、必要に応じて、通常、医薬品、医薬部外品、化粧料等の皮膚外用剤に配合されるタール系色素、酸化鉄等の着色顔料、パラベン、フェノキシエタノール等の防腐剤、ジメチルポリシロキサン、メチルフェニルポリシロキサン、環状シリコーン等のシリコーン油、パラフィン、ワセリン等の炭化水素類、オリーブスクワラン、米スクワラン、米胚芽油、ホホバ油、ヒマシ油、紅花油、オリーブ油、マカデミアナッツ油、ヒマワリ油等の植物油、ミツロウ、モクロウ、カルナバロウ等のロウ類、ミリスチン酸オクチルドデシル、パルミチン酸セチル、イソステアリン酸イソステアリル、ミリスチン酸イソプロピル等のエステル油、エタノール等の低級アルコール類、セタノール、ベヘニルアルコール、ステアリルアルコール、長鎖分岐脂肪族アルコール等の高級アルコール類、コレステロール、フィトステロール、分岐脂肪酸コレステロールエステル、マカデミアナッツ脂肪酸フィトステリルエステル等のステロール類及び誘導体、硬化油等の加工油類、
【0022】
ステアリン酸、ミリスチン酸、イソステアリン酸、オレイン酸、イソ型長鎖脂肪酸、アンテイソ型長鎖脂肪酸等の高級脂肪酸、リモネン、水素添加ビサボロール等のテルペン類、トリカプリル・カプリン酸グリセリル、2−エチルヘキサン酸グリセリル、トリイソ型長鎖脂肪酸グリセリル、トリパルミチン酸グリセリル等のトリグリセリド、セチル硫酸ナトリウム、N−ステアロイル−L−グルタミン酸塩等の陰イオン界面活性剤、ポリオキシエチレンアルキルエーテル、ポリオキシエチレン脂肪酸エステル、ポリオキシエチレン多価アルコール脂肪酸エステル、ポリオキシエチレン硬化ヒマシ油、多価アルコール脂肪酸エステル、ポリグリセリン脂肪酸エステル、変性シリコン、蔗糖エステル等の非イオン界面活性剤、テトラアルキルアンモニウム塩等の陽イオン界面活性剤、ベタイン型、スルホベタイン型、スルホアミノ酸型等の両性界面活性剤、レシチン、リゾフォスファチジルコリン、セラミド、セレブロシド等の天然系界面活性剤、酸化チタン、酸化亜鉛等の顔料、ジブチルヒドロキシトルエン等の抗酸化剤、塩化ナトリウム、塩化マグネシウム、硫酸ナトリウム、硝酸カリウム、硫酸ナトリウム、メタ珪酸ナトリウム、塩化カルシウム等の無機塩類、クエン酸ナトリウム、酢酸カリウム、琥珀酸ナトリウム、アスパラギン酸ナトリウム、乳酸ナトリウム、ジクロロ酢酸、メバロン酸、グリチルリチン酸等の有機酸及びその塩、塩酸エタノールアミン、硝酸アンモニウム、塩酸アルギニン、ジイソプロピルアミン塩、尿素、デカルボキシカルノシン等の有機アミン類及びその塩、エデト酸等のキレート剤、キサンタンガム、カルボキシビニルポリマー、カラギーナン、ペクチン、アルキル変性カルボキシビニルポリマー、寒天等の増粘剤、水酸化カリウム、ジイソプロパノールアミン、トリエタノールアミン等の中和剤、ヒドロキシメトキシベンゾフェノンスルフォン酸塩等の紫外線吸収剤、ジプロピレングリコール、1,3−ブチレングリコール、グリセリン、プロピレングリコール、ソルビトール、マルビトール、ジグリセリン、ラフィノース等の多価アルコール、各種アミノ酸、アスコルビン酸、ビオチン、トコフェロール等のビタミン類及びアスコルビン酸硫酸エステル塩、アスコルビン酸燐酸エステル塩、ニコチン酸トコフェロール等のビタミン誘導体等を本発明の目的を達成する範囲内で適宜配合することができる。
【0023】
【実施例】
以下、本発明による活性酸素消去効果、ヒアルロン酸合成促進・分解抑制効果およびアクアポリン合成促進効果を明らかにするための実施例等を示す。尚、本発明はこれらに限定されるものではない。
【0024】
試料:ノウゼンハレン抽出物
ノウゼンハレン抽出物は、ノウゼンハレン抽出物凍結乾燥品(試料1;丸善製薬社製)、ノウゼンハレン50%エタノール抽出溶液(試料2;丸善製薬社製)を用いた。
【0025】
・活性酸素消去効果試験(実施例1)
活性酸素を消去する効果を測定する方法は各種あるが、今回は活性酸素の一つであるスーパーオキシド(O )の消去効果を測定した。方法は以下に示す通りである。すなわち、キサンチン−キサンチンオキシダーゼ系により活性酸素の一つであるスーパーオキシド(O )を発生させ、試料溶液によるその消去率を求めた。スーパーオキシド(O )はニトロブルーテトラゾリウムと反応させて、ジホルマザンとし、560nmの吸光度により測定した(NBT法)。
【0026】
50mmol/L炭酸ナトリウム緩衝液(pH10.2)2.4mL、3.0mmol/Lキサンチン0.1mL、3.0mmol/Lエチレンジアミン四酢酸二ナトリウム0.1mL、0.15%牛血清アルブミン0.1mL、及び0.75mmol/Lニトロブルーテトラゾリウム0.1mLを含む発色試液2.9mLに対し、試料溶液0.1mLを加え、25℃で恒温にし、キサンチンオキシダーゼ(0.5単位/mL)を含む酵素液0.1mLを加えて攪拌した後、25℃にて20分間放置した。6.0mmol/L塩化第二銅を含む反応停止液0.1mLを加えて分光光度計にて560nmの吸光度を測定し、その値をSとした。試薬ブランクは発色試液2.9mL及び試料溶液0.1mLを取り、25℃で恒温にし、酵素液の代りにリン酸緩衝液0.1mLを加えて、以下同様にして分光光度計にて560nmの吸光度を測定し、その値をS’とした。コントロールは、発色試液2.9mL及び試料溶液の代りにそれぞれの希釈溶液0.1mLを用い、以下同様にして分光光度計にて560nmの吸光度を測定し、その値をCとした。コントロールの試薬ブランクは発色試液2.9mL及び試料溶液の代りにそれぞれの希釈溶液0.1mLを用い、酵素液の代りに炭酸ナトリウム緩衝液0.1mLを加えて、以下同様にして分光光度計にて560nmの吸光度を測定し、その値をC’とした。各試料溶液濃度におけるスーパーオキシド消去率を下記式により計算し、片対数グラフの横軸に試料溶液濃度(対数)、縦軸にスーパーオキシド消去率をとり、このグラフからスーパーオキシド50%消去濃度(IC50)を求めた。尚、S、S’、C、C’は3回測定し、それぞれの平均値を用いた。
[式]
スーパーオキシド消去率(%)=100×[1−(S−S’)/(C−C’)]
【0027】
得られた結果を下記に示す。

Figure 2004168732
【0028】
Figure 2004168732
【0029】
上記より明らかなように、本発明に係るノウゼンハレン科植物抽出物は極めて低濃度でスーパーオキシドを消去することが認められた。
【0030】
ヒアルロン酸合成促進・分解抑制効果を明らかにするための実施例を示す。
(1)ヒアルロン酸合成促進効果(実施例2)
・MEM培地の調製法
Minimum Essential Medium (大日本製薬社製、10−101) 10.6gにそれぞれ終濃度として、1%(V/V)Non Essential Amino Acid(大日本製薬社製、16−810)、1mmol/Lピルビン酸ナトリウム(大日本製薬社製、16−820)、1.2%(W/V)炭酸水素ナトリウム、蒸留水を加えて1Lとした後、炭酸ガスを吹き込んでpHを約7にした(以下、MEM培地と略記する)。
【0031】
・ウシ胎仔血清(FBS)の非働化
FBS(Irvine Scientific社製)を56℃で30分間加熱処理した。
【0032】
・プロナーゼ溶液
200μg/mLプロナーゼ(カルビオケム−ベーリング・コーポレイション社製、Streptomyces griseus由来)、0.15mol/L塩化ナトリウムおよび0.02%アジ化ナトリウム含有0.5mol/Lトリス塩酸緩衝液(pH8.0)。
【0033】
・細胞培養
正常ヒト線維芽細胞株〔デトロイト551株(ATCC CCL 110)〕を0.6×10個/ウェルの密度で24ウェルプレートに播種し、10%(V/V)の非働化FBSを含むMEM培地にて95%(V/V)空気−5%(V/V)炭酸ガスの雰囲気下、37℃で3日間静置培養し、さらに無血清MEM培地にて1日間培養した。次いで、試料を添加した培地にて3日間培養後、培養上清を回収し上清中のヒアルロン酸量を求めた。
【0034】
・ヒアルロン酸産生量の測定
培養上清0.63mLにプロナーゼ溶液0.07mLを加え、37℃で18時間静置した後、100℃で10分間加熱処理し、プロナーゼを失活させた。次に、反応液0.01mLからヒアルロン酸プレート「中外」(中外診断科学社製)を用い、添付説明書に従いヒアルロン酸量を測定した。尚、試料添加は各群n=3で試験を行い、結果はそれぞれの平均値を用いた。
【0035】
得られた結果を下記に示す。
Figure 2004168732
【0036】
Figure 2004168732
【0037】
上記より明らかなように、本発明に係るノウゼンハレン科植物抽出物は極めて低濃度でヒアルロン酸合成促進効果を有することが認められた。
【0038】
(2)ヒアルロン酸分解抑制効果(実施例3)
・細胞添加用高分子トリチウムヒアルロン酸の調製方法
正常ヒト線維芽細胞株〔デトロイト551株(ATCC CCL 110)〕の細胞数を10%(V/V)の非働化FBSを含むMEM培地にて2×10個/mLに調整し、225cmのフラスコに50mL入れ、3日間培養しコンフルエント状態にした。その後ヒアルロン酸の前駆体であるトリチウムグルコサミン(American Radiolabeled Chemicals Inc.社製)を培養系に添加し(10μCi/mL)、さらに3日間培養したのち、培養液からトリチウムラベルされたヒアルロン酸をUnderhillらの方法(J.Cell Biology,82巻,475頁,1979年)によって精製し、さらにゲルろ過カラムにより分子量100万以上の高分子トリチウムヒアルロン酸(比放射活性,0.1μCi/μg)を調製した。これを細胞培養系への添加用高分子トリチウムヒアルロン酸とした。
【0039】
・正常ヒト線維芽細胞への高分子トリチウムヒアルロン酸の添加培養
正常ヒト線維芽細胞株〔デトロイト551株(ATCC CCL 110)〕の細胞数を10%(V/V)の非働化FBSを含むMEM培地にて1.5×10個/mLに調整し、12穴プレート(ファルコン社製)に0.8mLずつ播種し、95%(V/V)空気−5%(V/V)炭酸ガスの雰囲気下、37℃で3日間静置培養し、さらに、MEM培地のみに培地交換し、1日間培養した。その後、高分子トリチウムヒアルロン酸を含む(1μCi/mL;37MBq/mL,10μg/mL)MEM培地を調製し、培地交換をし、3日間培養を行った。
【0040】
・細胞による高分子トリチウムヒアルロン酸の分解評価
培養終了後、培養液を回収し、100℃で5分間加熱処理を行った後、培地1mLをセファロースCL−2Bカラム(内径1cm,長さ60cm)にアプライし以下の条件でゲルろ過を行った。流速:0.6mL/min、分画:4mL/1Fraction、分画総数:25、更に分子量10万以下のヒアルロン酸が溶出するフラクション10〜25の16本を集め、[H]放射活性を測定し分解したヒアルロン酸の量を求めた。分解抑制率は以下の式を用いて算出した。
分解抑制率=(試料無添加時の放射活性−試料添加時の放射活性)×100
/試料無添加時の放射活性
【0041】
得られた結果を下記に示す。尚、試料添加は各群n=3で試験を行い、結果はそれぞれの平均値を用いた。
Figure 2004168732
【0042】
Figure 2004168732
【0043】
上記より明らかなように、本発明に係るノウゼンハレン科植物抽出物は極めて低濃度でヒアルロン酸分解抑制効果を有することが認められた。
【0044】
アクアポリン合成促進効果を明らかにするための実施例等を示す(比較例1、実施例4〜6)。
・培養表皮細胞
ヒト正常表皮角化細胞は市販品(Epidercell/新生児***:クラボウ社製)を用いた。
【0045】
・表皮細胞培養用培地
MCDB153HAA(和光純薬社より購入)をベースとし、ハイドロコーチゾン(0.5μmol/L)、エタノールアミン(0.1mmol/L)、ホスホエタノールアミン(0.1mmol/L)、インシュリン(5μg/mL)、及びEGF(上皮細胞成長因子:10ng/mL)を加えたK−GM培地を調製した。培養には、これにBPE(牛脳下垂体抽出液、クラボウ社より購入)を培地1mL当たり4μL添加し、表皮細胞培養用培地とした。
【0046】
・試料添加と表皮細胞抽出物の調製
正常ヒト表皮細胞の細胞数を表皮細胞培養用培地にて2.0×10個/mLに調整し、24穴プレート(ファルコン製)に1.0mLずつ播種した。培養は、95%(V/V)空気−5%(V/V)炭酸ガスの雰囲気下37℃で行い、培養5日目に試料を添加し、さらに1日間培養した。培養後、培地を除き250μLの抽出バッファー(100mmol/L Tris−Cl pH9.0、1% SDS、9mol/L尿素)を添加し細胞を溶解させ、さらに500μLの水を加え、これを細胞抽出液とした。
【0047】
・ウェスタンブロッティング
・SDSポリアクリルアミドゲル電気泳動;
細胞抽出液8μL、4倍濃縮SDS Sample Buffer(インビトロジェン社)4μL、10倍濃縮 Sample Reducing Agent(インビトロジェン社) 1.6μL、水 2.4μLを混合し、70℃10分加熱後、電気泳動に供した。電気泳動は4−12% Bis−Tris Gel(インビトロジェン社)を用い、NuPAGE GelSystem(インビトロジェン社)の添付説明書に従った。
【0048】
・タンパク質のPVDF膜への転写;
転写は、Xcell II Blot Module(インビトロジェン社)を使用し、添付説明書に従った。PVDF膜は Immobilon(ミリポア社)を使用した。
【0049】
・免疫学的検出;
転写後のPVDF膜は、ブロッキング試薬(5%濃度にスキムミルクを0.05%Tween−20含有PBSに溶解した試薬)に室温で30分浸した後、ブロッキング試薬で3000倍に希釈したヒトアクアポリン−3抗体と4℃で24hr反応させた。なお、ヒトアクアポリン−3抗体は、ヒトアクアポリン−3アミノ酸配列のC末端側ペプチドを合成し、これを免疫したウサギの血清より作製し、希釈倍率は適切な検出シグナルを得るために事前に設定した。次に、PVDF膜を0.05%Tween−20含有PBS中で振盪洗浄し、0.05%Tween−20含有PBSで2000倍に希釈した抗ウサギIgG抗体(DAKO社製)と室温で45分反応させた。最後に、PVDF膜を0.05%Tween−20含有PBS中で振盪洗浄後、SuperSignal(PIERCE社製)を用い添付説明書に従いシグナルを検出した。結果を図1に示す。尚、Tween−20は、Uniqema Americas社商品名である。
【0050】
試料無添加群(比較例1)と比べ、ノウゼンハレン抽出物凍結乾燥品0.001%(実施例4)、0.01%添加群(実施例5)、ノウゼンハレン50%エタノール抽出溶液0.1%添加群(実施例6)では顕著な検出シグナル強度の増加が認められた。これより明らかなように、本発明に係るノウゼンハレン科植物抽出物は極めて低濃度でアクアポリン合成促進効果を有することが認められた。
【0051】
以下、本発明の活性酸素消去剤、ヒアルロン酸合成促進・分解抑制剤、およびアクアポリン合成促進剤の処方例を示す。
【0052】
処方例1〜3(スキンクリーム)
試料1又は2の活性酸素消去剤、ヒアルロン酸合成促進・分解抑制剤、およびアクアポリン合成促進剤を表1の組成でそれぞれを配合しスキンクリームを調製した(処方例1〜3)。
【0053】
(1)組成
【表1】
Figure 2004168732
【0054】
(2)調製法
(A)成分および(B)成分を各々80℃に加熱溶解した後混合して、攪拌しつつ冷却し、30℃まで冷却して、スキンクリームを調製した。
【0055】
処方例4〜6(ローション)
試料1又は2の活性酸素消去剤、ヒアルロン酸合成促進・分解抑制剤、およびアクアポリン合成促進剤を表2の組成で配合し、ローションを調製した(処方例4〜6)。
【0056】
(1)組成
【表2】
Figure 2004168732
【0057】
(2)調製法
各成分をそれぞれ混合溶解し、攪拌して、ローションを調製した。
【0058】
処方例7〜9(ジェル)
試料1又は2の活性酸素消去剤、ヒアルロン酸合成促進・分解抑制剤、およびアクアポリン合成促進剤を表3の組成でそれぞれを配合しジェルを調製した(処方例7〜9)。
【0059】
(1)組成
【表3】
Figure 2004168732
【0060】
(2)調製法
(A)成分および(B)成分を各々60℃に加熱溶解した後混合して、攪拌しつつ冷却し、30℃まで冷却して、ジェルを調製した。
【0061】
処方例10〜12(ジェル)
試料1又は2の活性酸素消去剤、ヒアルロン酸合成促進・分解抑制剤、およびアクアポリン合成促進剤を表4の組成でそれぞれを配合しジェルを調製した(処方例10〜12)。
【0062】
(1)組成
【表4】
Figure 2004168732
【0063】
(2)調製法
(A)成分および(B)成分を各々60℃に加熱溶解した後混合して、攪拌しつつ冷却し、30℃まで冷却して、ジェルを調製した。
【0064】
処方例13〜15(親油クリーム)
試料1又は2の活性酸素消去剤、ヒアルロン酸合成促進・分解抑制剤、およびアクアポリン合成促進剤を表5の組成で配合し、親油クリームを調製した(処方例13〜15)。
【0065】
(1)組成
【表5】
Figure 2004168732
【0066】
(2)調製法
A)成分および(B)成分を各々60℃に加熱溶解した後混合して、攪拌しつつ冷却し、30℃まで冷却して、親油クリームを調製した。
【0067】
処方例16〜18(サンスクリーン)
試料1又は2の活性酸素消去剤、ヒアルロン酸合成促進・分解抑制剤、およびアクアポリン合成促進剤を表6の組成でそれぞれを配合しサンスクリーンを調製した(処方例16〜18)。
【0068】
(1)組成
【表6】
Figure 2004168732
【0069】
(2)調製法
(A)成分および(B)成分を各々80℃に加熱溶解した後混合して、攪拌しつつ冷却し、30℃まで冷却して、サンスクリーンを調製した。
【0070】
処方例19〜21(入浴剤)
試料1又は2の活性酸素消去剤、ヒアルロン酸合成促進・分解抑制剤、およびアクアポリン合成促進剤を表7の組成でそれぞれを配合し入浴剤を調製した(処方例19〜21)。
【0071】
(1)組成
【表7】
Figure 2004168732
【0072】
(2)調製法
(A)成分および(B)成分を各々60℃に加熱溶解した後混合して、攪拌しつつ冷却し、30℃まで冷却して、入浴剤を調製した。
【0073】
次に、効果を示すための試験例を示す。
【0074】
下記記載の組成のスキンローション及び入浴剤を、それぞれの調製法に従い調製した。
【0075】
試験例1〜3及び比較例2:スキンローション
配合成分 配合量(%)
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
(アルコール相)
95%エチルアルコール 15.0
ポリオキシエチレン(60モル)硬化ヒマシ油 2.0
パラオキシ安息香酸メチル 0.05
香料 適 量
試料(表8記載) 表8記載の量
(水相)
グリセリン 5.0
クエン酸ナトリウム 適 量
イオン交換水 残 余
(合計) 100.0
【0076】
Figure 2004168732
【0077】
・スキンローションの調製法
水相、アルコール相を各々均一に溶解し、そして水相とアルコール相とを混合攪拌分散し可溶化を行い、次いで容器に充填する。使用時には内容物を均一に振盪分散して使用する。
【0078】
上記で調製したスキンローションを用いて使用試験を行い、皮膚老化防止効果及び美白効果を調べた。試験方法は下記に示す通りである。
【0079】
・試験方法
80名の女性被験者の顔面を左右に分け、一方に上記の試験例1〜3、他方に比較例2のスキンローションを毎日2回以上塗布してもらい、2ヵ月後比較例2を基準として下記の判定基準により各評価項目について評点を出してもらい、評点の合計値により評価した。被験者を1群20名にわけて3群とし、試験例1〜3の各スキンローションについて試験を行った。その結果を表9に示す。
【0080】
Figure 2004168732
【0081】
[表9]
評価項目 試験例1 試験例2 試験例3
−−−−−−−−−−−−−−−−−−−−−−−−
肌荒れ防止 25 20 41
肌のつや 27 21 43
肌のはり 31 28 45
肌の明るさ 29 22 39
しわ改善 24 19 37
【0082】
表9より明らかなように、本発明に係るノウゼンハレン抽出物凍結乾燥品を有効成分として含有するスキンローションは、肌荒れを防止し、肌のつや、はり、明るさを保ち、しわを改善する効果に優れ、皮膚老化防止用及び美白用の皮膚化粧料として用いることができることが明らかとなった。
【0083】
試験例4:入浴剤
配合成分 配合量(%)
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
硫酸ナトリウム 85.0
香料及び界面活性剤 適 量
有機色素 適 量
ノウゼンハレン抽出物凍結乾燥品 10.0
炭酸水素ナトリウム 残 量
(合計) 100.0
【0084】
・入浴剤の調製法
各成分を混合し入浴剤を調製した。尚、この入浴剤は使用時に約3000倍に希釈される。
【0085】
上記入浴剤を被験者20名に三週間毎日の入浴時に使用させた。結果、肌荒れ防止、肌のつや、はり、明るさの保持、しわの改善において効果が認められた。尚、本発明に係るスキンローション及び入浴剤による発赤や乾燥等の異常は認められなかった。
【0086】
【発明の効果】
以上説明したように、皮膚の保湿性改善、肌荒れ防止、老化防止に有効な活性酸素消去剤、ヒアルロン酸合成促進・分解抑制剤及びアクアポリン合成促進剤を提供できることは明らかである。
【図面の簡単な説明】
【図1】ヒト正常表皮角化細胞におけるノウゼンハレン抽出物のアクアポリン合成促進効果を示す図である。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to an active oxygen scavenger, a hyaluronic acid synthesis promoter, a hyaluronic acid decomposition inhibitor, and an aquaporin synthesis promoter, and more particularly, eliminates active oxygen to suppress the production of lipid peroxide in the skin, Active oxygen scavenging that promotes hyaluronic acid-producing ability of cells, suppresses resolution, and promotes aquaporin synthesis of skin cells, which is expected to have excellent moisturizing properties on skin, improve rough skin, prevent aging and whitening effect The present invention relates to an agent, a hyaluronic acid synthesis promoter and a decomposition inhibitor, and an aquaporin synthesis promoter.
[0002]
[Prior art]
Aged skin has increased lipid peroxide, loss of flexibility and elasticity, increased skin wrinkling, and dry, non-smooth rough skin symptoms. As one of the substances causing these skin symptoms, so-called active oxygen, which is generated by oxygen in the atmosphere under the influence of ultraviolet rays and enzymes, is considered. Such active oxygen includes superoxide, hydroxy radical, singlet oxygen, hydrogen peroxide and the like. This active oxygen oxidizes the fatty acids to form peroxides. In addition, the generated peroxide and active oxygen have adverse effects on the living body, such as collagen fiber cross-linking, hyaluronic acid fragmentation, DNA helix partial cleavage, and tissue damage due to the generation of chain radicals. As a result, it is said to promote aging of the living body such as skin wrinkles, loss of elasticity, and hair loss.
[0003]
On the other hand, pigmentation on the skin such as darkness, spots, and freckles due to sunburn is considered to be caused by the production of melanin, a black-brown amorphous pigment. Melanin is produced by tyrosinase converting tyrosine to dopa and dopa to dopaquinone in melanosomes in pigment cells called melanocytes present in the basal layer of the epidermis, and then undergoing oxidative polymerization via various melanin intermediate metabolites. It is said that active oxygen generated by ultraviolet rays activates the oxidation reaction of this system, so that melanin is excessively generated and pigmentation on skin is promoted.
[0004]
Therefore, elimination of active oxygen is very important for skin in terms of improving or preventing skin aging and pigmentation, and is an important factor required for anti-aging skin cosmetics.
[0005]
Therefore, conventionally, a search for a substance having an action of eliminating active oxygen generated in a living body has been widely performed. Substances having such an action which have been conventionally used include those derived from natural products, such as fat-soluble tocopherol (vitamin E) and water-soluble ascorbic acid (vitamin C). Examples include BHT (butylhydroxytoluene) and BHA (butylhydroxyanisole). However, these substances are not sufficient in scavenging active oxygen, and BHA is suspected of having carcinogenicity in a synthetic compound, and none of them is practically usable as an active oxygen scavenger. Therefore, there is a strong demand for an active oxygen scavenger that has a sufficient action of eliminating active oxygen generated in a living body, is highly safe, and has good applicability to skin and the like.
[0006]
From the aspect of preventing skin aging, it is also important to increase the production of hyaluron in the skin. Hyaluronic acid retains water in the intercellular space, retains cells based on the formation of a jelly-like matrix in the tissue, maintains the lubricity and flexibility of the tissue, resists external forces such as mechanical damage, and It has many functions such as prevention of bacterial infection (for example, Non-Patent Document 1).
[0007]
It is said that hyaluronic acid in the skin decreases with age, resulting in aging such as fine wrinkles and dryness. Numerous cosmetics containing collagen and hyaluronic acid have been proposed as such aging skin improving agents, but only those that improve the moisturizing effect on the surface and do not essentially improve aging skin. Absent. Therefore, it is effective to prevent skin aging by enhancing the hyaluronic acid production performance of skin cells and suppressing the resolution.
[0008]
In addition to the above-mentioned effects of eliminating active oxygen and increasing hyaluronic acid on the skin, which have been shown to have excellent effects on the skin, recent studies have shown that aquaporins present in skin cells play an important role in skin physiology. It became clear.
[0009]
Aquaporin (hereinafter abbreviated as AQP) is also called a water channel and is known as a membrane protein that selectively allows water to permeate. To date, 11 types of AQP genes (AQP0 to AQP10) have been discovered in humans, and among them, AQP3, AQP7, and AQP9 transmit not only water but also nonionic small molecules such as glycerol and urea. Also, looking at the distribution of AQP expression in human tissues, it is clear that most organs have a plurality of AQPs.
[0010]
Regarding the expression of AQP in the epidermis, recent studies by the present inventors have reported the expression of AQP3, AQP5, and AQP9 genes in cultured human keratinocytes and model skin epidermis. Among them, AQP3 expression in cultured human keratinocytes is increased by hyperosmotic stress, and thus AQP3 is considered to be one important factor that controls the water environment of keratinocytes (see Non-Patent Document 2). Also, in the skin of AQP3 gene-deficient mice, decreased horny layer water content, skin viscoelasticity, and barrier recovery were observed, indicating that AQP3 is deeply involved in skin physical properties and skin physiology (Non-patent Literature) 3). Therefore, promotion of aquaporin production can be expected to suppress skin dryness, adjust the beam, and enhance the barrier function. However, there are no known aquaporin synthesis promoters and skin cosmetics that have sufficient aquaporin synthesis promoting action, are highly safe, and have good applicability to skin and the like.
[0011]
[Non-patent document 1]
"BIO INDUSTRY" Vol. 8, 1991, p. 346
[Non-patent document 2]
"Biochimica et Biophysica Acta", Vol. 1522, 2001, pp. 82-88)
[Non-Patent Document 3]
"Journal of Dermatological Science", Vol. 29, p. 143
[0012]
[Problems to be solved by the invention]
Under such circumstances, an object of the present invention is to eliminate active oxygen, suppress the production of lipid peroxide in the skin, promote the ability of skin cells to produce hyaluronic acid, suppress the resolution, and furthermore, It is an object of the present invention to provide an active oxygen scavenger, a hyaluronic acid synthesis acceleration / decomposition inhibitor, and an aquaporin synthesis accelerator having excellent moisturizing properties on skin, improvement of rough skin, prevention of aging and whitening by promoting aquaporin synthesis.
[0013]
[Means for Solving the Problems]
In view of the above circumstances, the present inventors have conducted intensive studies, and as a result, the extract obtained from the Nosenharenaceae plant has an excellent active oxygen scavenging effect, a hyaluronic acid synthesis promotion / decomposition suppression effect, and an aquaporin synthesis promotion effect, and The present inventors have found that the dryness, rough skin, aging and pigmentation can be effectively improved or prevented, and the present invention has been completed.
[0014]
That is, the present invention resides in an active oxygen scavenger, a hyaluronic acid synthesis promotion / decomposition inhibitor, and an aquaporin synthesis promoter, characterized by containing an extract obtained from a plant of the family Nosenharenaceae.
[0015]
BEST MODE FOR CARRYING OUT THE INVENTION
Hereinafter, embodiments of the present invention will be described in detail.
[0016]
The Rhododendronaceae plant used in the present invention is a succulent herb with prominent stems, and its place of origin is limited to central and southern South Africa from Mexico to Patagonia. The most famous ornamental one is Tropaeolum majus, which is also called nasturtium (gold lotus flower) and is cultivated in flower beds and potted plants. Also, immature seeds are sometimes pickled and eaten instead of capers.
[0017]
Examples of the extraction solvent for obtaining the Russula plant extract of the present invention include water, alcohols such as methanol, ethanol and isopropyl alcohol, polyhydric alcohols such as ethylene glycol, propylene glycol and 1,3-butylene glycol, and acetone. Or a mixture of one or more of ketones such as ethyl acetate, esters such as ethyl acetate, ethers such as diethyl ether, and aromatic compounds such as benzene.
[0018]
The extract of Rusticaceae may be used as an extraction solvent solution, or may be dried and concentrated by a conventional method. Further, filtration, re-extraction, and the like may be performed.
[0019]
The active oxygen scavenger, hyaluronic acid synthesis accelerator / decomposition inhibitor and aquaporin synthesis accelerator of the present invention are, for example, ointments, lotions, emulsions, creams, packs, powders, granules, etc. Can be used in any dosage form. Examples of the form of use include skin cosmetics. The base of the skin cosmetic may be a known external base, and is not particularly limited. It can be expected to be applied to all skin on the human body including the scalp as the skin to be applied.
[0020]
The amount of the active oxygen scavenger, the hyaluronic acid synthesis accelerating / degrading inhibitor and the aquaporin synthesis accelerating agent of the extract of Rusticaceae plant of the present invention varies depending on the system used, and cannot be said unconditionally. When the amount is 0.00001 to 10.0% by mass in terms of dry matter (hereinafter referred to as% unless otherwise specified), the active oxygen scavenging effect, the hyaluronic acid synthesis promotion / decomposition suppression effect, and the aquaporin synthesis of the present invention are obtained. It is preferable to obtain an accelerating effect, and has a good feel at the time of use, and can stably maintain individual dosage forms. If the amount is less than 0.00001%, the effect may not be sufficiently exhibited, while if the amount exceeds 10.0%, the effect corresponding to the amount may not be obtained.
[0021]
The active oxygen scavenger, the hyaluronic acid synthesis accelerating / degrading inhibitor and the aquaporin synthesis accelerating agent of the present invention, if necessary, are usually used in pharmaceuticals, quasi-drugs, cosmetics and other external skin preparations. -Based pigments, coloring pigments such as iron oxide, preservatives such as paraben and phenoxyethanol, silicone oils such as dimethylpolysiloxane, methylphenylpolysiloxane and cyclic silicone, hydrocarbons such as paraffin and petrolatum, olive squalane, rice squalane, rice Germ oil, jojoba oil, castor oil, safflower oil, olive oil, macadamia nut oil, sunflower oil, and other vegetable oils, beeswax, mocro, carnauba wax and other waxes, octyl dodecyl myristate, cetyl palmitate, isostearyl isostearate, isopropyl myristate Such as ester oil, ethanol, etc. Higher alcohols such as lower alcohols, cetanol, behenyl alcohol, stearyl alcohol, and long-chain branched aliphatic alcohols; sterols and derivatives such as cholesterol, phytosterol, branched fatty acid cholesterol ester, and macadamia nut fatty acid phytosteryl ester; and processing oils such as hardened oil. Kind,
[0022]
Higher fatty acids such as stearic acid, myristic acid, isostearic acid, oleic acid, iso long chain fatty acids and anteiso long chain fatty acids, terpenes such as limonene, hydrogenated bisabolol, glyceryl tricapryl caprate, glyceryl 2-ethylhexanoate , Triglycerides such as triiso long chain fatty acid glyceryl, glyceryl tripalmitate, anionic surfactants such as sodium cetyl sulfate, N-stearoyl-L-glutamate, polyoxyethylene alkyl ether, polyoxyethylene fatty acid ester, polyoxy Nonionic surfactants such as ethylene polyhydric alcohol fatty acid ester, polyoxyethylene hydrogenated castor oil, polyhydric alcohol fatty acid ester, polyglycerin fatty acid ester, modified silicone, sucrose ester, etc. Cationic surfactants such as ammonium salts, amphoteric surfactants such as betaine type, sulfobetaine type and sulfoamino acid type, natural surfactants such as lecithin, lysophosphatidylcholine, ceramide, cerebroside, titanium oxide, and oxidation Pigments such as zinc, antioxidants such as dibutylhydroxytoluene, inorganic salts such as sodium chloride, magnesium chloride, sodium sulfate, potassium nitrate, sodium sulfate, sodium metasilicate, calcium chloride, sodium citrate, potassium acetate, sodium succinate, Organic acids and salts thereof such as sodium aspartate, sodium lactate, dichloroacetic acid, mevalonic acid, and glycyrrhizic acid; organic amines such as ethanolamine hydrochloride, ammonium nitrate, arginine hydrochloride, diisopropylamine salt, urea, and decarboxycarnosine; Salts, chelating agents such as edetic acid, xanthan gum, carboxyvinyl polymer, carrageenan, pectin, alkyl-modified carboxyvinyl polymer, thickeners such as agar, potassium hydroxide, diisopropanolamine, neutralizing agents such as triethanolamine, UV absorbers such as hydroxymethoxybenzophenone sulfonate, dipropylene glycol, 1,3-butylene glycol, glycerin, propylene glycol, sorbitol, malbitol, diglycerin, polyhydric alcohols such as raffinose, various amino acids, ascorbic acid, biotin, Vitamins such as tocopherol and ascorbic acid sulfates, ascorbic acid phosphates, vitamin derivatives such as tocopherol nicotinate and the like are appropriately blended within a range that achieves the object of the present invention. Can be
[0023]
【Example】
Examples for clarifying the active oxygen elimination effect, the hyaluronic acid synthesis promotion / decomposition suppression effect, and the aquaporin synthesis promotion effect according to the present invention will be described below. Note that the present invention is not limited to these.
[0024]
Sample: Nosenhalen extract
As the Nosenhallen extract, a freeze-dried Nosenhallen extract (Sample 1; Maruzen Pharmaceutical Co., Ltd.) and a 50% ethanol extract of Nosenhallen (Sample 2; Maruzen Pharmaceutical Co., Ltd.) were used.
[0025]
・ Active oxygen scavenging effect test (Example 1)
There are various methods for measuring the effect of eliminating active oxygen, but this time, superoxide (O2 ) Was measured. The method is as follows. That is, the superoxide (O 2) which is one of the active oxygens by the xanthine-xanthin oxidase system2 ) Was generated and its erasure rate by the sample solution was determined. Superoxide (O2 ) Was reacted with nitroblue tetrazolium to form diformazan and measured by absorbance at 560 nm (NBT method).
[0026]
2.4 mL of 50 mmol / L sodium carbonate buffer (pH 10.2), 0.1 mL of 3.0 mmol / L xanthine, 0.1 mL of 3.0 mmol / L disodium ethylenediaminetetraacetate, 0.1 mL of 0.15% bovine serum albumin 0.1 mL of a sample solution is added to 2.9 mL of a color developing solution containing 0.1 mL of 0.75 mmol / L nitro blue tetrazolium, and the temperature is kept at 25 ° C. to give an enzyme containing xanthine oxidase (0.5 units / mL). After 0.1 mL of the liquid was added and stirred, the mixture was left at 25 ° C. for 20 minutes. 0.1 mL of a reaction stop solution containing 6.0 mmol / L cupric chloride was added, and the absorbance at 560 nm was measured with a spectrophotometer. For the reagent blank, take 2.9 mL of the color reagent solution and 0.1 mL of the sample solution, keep the temperature at 25 ° C., add 0.1 mL of phosphate buffer in place of the enzyme solution, and repeat the same procedure with a spectrophotometer at 560 nm. The absorbance was measured, and the value was defined as S '. As a control, 2.9 mL of the color reagent solution and 0.1 mL of each diluted solution were used in place of the sample solution. Absorbance at 560 nm was measured using a spectrophotometer in the same manner as above, and the value was designated as C. For the control reagent blank, use 2.9 mL of the color reagent and 0.1 mL of each diluted solution in place of the sample solution, add 0.1 mL of sodium carbonate buffer in place of the enzyme solution, and apply the same procedure to the spectrophotometer in the same manner. The absorbance at 560 nm was measured and the value was taken as C ′. The superoxide elimination rate at each sample solution concentration was calculated by the following equation. The horizontal axis of the semilogarithmic graph was the sample solution concentration (log), and the vertical axis was the superoxide elimination rate. From this graph, the superoxide 50% erasure concentration ( IC50) was determined. In addition, S, S ', C, and C' were measured three times, and the average value of each was used.
[formula]
Superoxide erasure rate (%) = 100 × [1- (S−S ′) / (C−C ′)]
[0027]
The results obtained are shown below.
Figure 2004168732
[0028]
Figure 2004168732
[0029]
As is clear from the above, it was confirmed that the extract of the family Rusticaceae according to the present invention eliminated superoxide at an extremely low concentration.
[0030]
An example for clarifying the effect of promoting hyaluronic acid synthesis and inhibiting decomposition will be described.
(1) Hyaluronic acid synthesis promoting effect (Example 2)
・ Preparation method of MEM medium
Minimum Essential Medium (Dainippon Pharmaceutical Co., Ltd., 10-101) As a final concentration in 10.6 g, 1% (V / V) Non Essential Amino Acid (Dainippon Pharmaceutical Co., Ltd., 16-810), 1 mmol / L pyruvine Sodium acid (Dainihon Pharmaceutical Co., Ltd., 16-820), 1.2% (W / V) sodium bicarbonate, and distilled water were added to make up to 1 L, and then carbon dioxide was blown to adjust the pH to about 7 (hereinafter, referred to as “pH”). , MEM medium).
[0031]
・ Inactivation of fetal bovine serum (FBS)
FBS (Irvine Scientific) was heat-treated at 56 ° C. for 30 minutes.
[0032]
・ Pronase solution
200 μg / mL pronase (from Streptomyces griseus, manufactured by Calbiochem-Bering Corporation), 0.5 mol / L Tris-HCl buffer (pH 8.0) containing 0.15 mol / L sodium chloride and 0.02% sodium azide.
[0033]
・ Cell culture
A normal human fibroblast cell line [Detroit 551 (ATCC CCL 110)] was 0.6 × 105The cells were seeded in a 24-well plate at a density of cells / well, and an atmosphere of 95% (V / V) air-5% (V / V) carbon dioxide gas in MEM medium containing 10% (V / V) inactivated FBS. The cells were cultured at 37 ° C. for 3 days, and further cultured in a serum-free MEM medium for 1 day. Next, after culturing for 3 days in the medium to which the sample was added, the culture supernatant was recovered, and the amount of hyaluronic acid in the supernatant was determined.
[0034]
・ Measurement of hyaluronic acid production
0.07 mL of the pronase solution was added to 0.63 mL of the culture supernatant, allowed to stand at 37 ° C. for 18 hours, and then heat-treated at 100 ° C. for 10 minutes to inactivate pronase. Next, the amount of hyaluronic acid was measured from 0.01 mL of the reaction solution using a hyaluronic acid plate “Chugai” (manufactured by Chugai Diagnostics Science) according to the attached instructions. In addition, the sample was added and the test was performed in each group n = 3, and the average value was used for the results.
[0035]
The results obtained are shown below.
Figure 2004168732
[0036]
Figure 2004168732
[0037]
As is clear from the above, it was confirmed that the extract of the family Rusticaceae according to the present invention has a hyaluronic acid synthesis promoting effect at an extremely low concentration.
[0038]
(2) Hyaluronic acid decomposition inhibitory effect (Example 3)
・ Preparation method of polymer tritium hyaluronic acid for cell addition
The number of cells of a normal human fibroblast cell line [Detroit 551 (ATCC CCL 110)] was increased to 2 × 10 4 in a MEM medium containing 10% (V / V) of inactivated FBS.5Adjust to pcs / mL, 225cm2Was placed in a flask and cultured for 3 days to obtain a confluent state. Thereafter, tritium glucosamine (manufactured by American Radioactive Chemicals Inc.), which is a precursor of hyaluronic acid, was added to the culture system (10 μCi / mL), and after further culturing for 3 days, tritium-labeled hyaluronic acid from the culture solution was extracted from Underhill et al. (J. Cell Biology, Vol. 82, p. 475, 1979), and a high molecular weight tritium hyaluronic acid (specific radioactivity, 0.1 μCi / μg) having a molecular weight of 1,000,000 or more was prepared using a gel filtration column. . This was used as a polymer tritium hyaluronic acid for addition to a cell culture system.
[0039]
・ Addition culture of high molecular weight tritium hyaluronic acid to normal human fibroblasts
The number of cells of a normal human fibroblast cell line [Detroit 551 (ATCC CCL 110)] was increased to 1.5 × 10 5 in MEM medium containing 10% (V / V) of inactivated FBS.50.8 mL per 12-well plate (manufactured by Falcon) and seeded at 37 ° C. for 3 days in an atmosphere of 95% (V / V) air-5% (V / V) carbon dioxide gas. The culture was allowed to stand, and the medium was changed to MEM medium only, followed by culturing for one day. Thereafter, a MEM medium containing high molecular tritium hyaluronic acid (1 μCi / mL; 37 MBq / mL, 10 μg / mL) was prepared, the medium was replaced, and the cells were cultured for 3 days.
[0040]
・ Evaluation of degradation of polymer tritium hyaluronic acid by cells
After completion of the culture, the culture solution was collected and subjected to a heat treatment at 100 ° C. for 5 minutes. Then, 1 mL of the medium was applied to a Sepharose CL-2B column (1 cm inside diameter, 60 cm length), and gel filtration was performed under the following conditions. . Flow rate: 0.6 mL / min, fractionation: 4 mL / 1 fraction, total number of fractions: 25, and 16 fractions of 10 to 25 fractions from which hyaluronic acid having a molecular weight of 100,000 or less eluted were collected.3H] The radioactivity was measured to determine the amount of decomposed hyaluronic acid. The decomposition inhibition rate was calculated using the following equation.
Degradation inhibition rate = (radioactivity when no sample is added−radioactivity when sample is added) × 100
/ Radioactivity without sample
[0041]
The results obtained are shown below. In addition, the sample was added and the test was performed with n = 3 in each group, and the average value was used for the results.
Figure 2004168732
[0042]
Figure 2004168732
[0043]
As is clear from the above, it was confirmed that the extract of the family Rusticaceae according to the present invention has a hyaluronic acid decomposition inhibitory effect at an extremely low concentration.
[0044]
Examples and the like for clarifying the effect of accelerating aquaporin synthesis are shown (Comparative Example 1, Examples 4 to 6).
・ Cultivated epidermal cells
As human normal epidermal keratinocytes, a commercially available product (Epidercell / neonatal foreskin: manufactured by Kurabo Industries) was used.
[0045]
・ Epidermal cell culture medium
Based on MCDB153HAA (purchased from Wako Pure Chemical Industries), hydrocortisone (0.5 μmol / L), ethanolamine (0.1 mmol / L), phosphoethanolamine (0.1 mmol / L), insulin (5 μg / mL) , And K-GM medium to which EGF (epithelial cell growth factor: 10 ng / mL) was added. For culture, BPE (bovine pituitary extract, purchased from Kurabo Industries) was added to the culture in an amount of 4 μL per 1 mL of the culture medium to obtain a culture medium for epidermal cells.
[0046]
・ Sample addition and preparation of epidermal cell extract
The number of normal human epidermal cells was determined to be 2.0 × 104And adjusted to 1.0 / mL and inoculated in a 24-well plate (Falcon) in an amount of 1.0 mL each. Culturing was performed at 37 ° C. in an atmosphere of 95% (V / V) air-5% (V / V) carbon dioxide, the sample was added on the 5th day of the culture, and the cells were further cultured for 1 day. After the culture, the medium was removed, 250 μL of an extraction buffer (100 mmol / L Tris-Cl pH 9.0, 1% SDS, 9 mol / L urea) was added to dissolve the cells, and 500 μL of water was further added. And
[0047]
・ Western blotting
-SDS polyacrylamide gel electrophoresis;
8 μL of cell extract, 4 μL of 4 × concentrated SDS Sample Buffer (Invitrogen), 4 μL of 10 × concentrated Sample Reducing Agent (Invitrogen), and 2.4 μL of water are mixed, heated at 70 ° C. for 10 minutes, and then subjected to electrophoresis. did. The electrophoresis was performed using 4-12% Bis-Tris Gel (Invitrogen) according to the instructions attached to NuPAGE GelSystem (Invitrogen).
[0048]
Transfer of proteins to PVDF membranes;
Transcription was performed using Xcell II Blot Module (Invitrogen) according to the attached instructions. The PVDF membrane used was Immobilon (Millipore).
[0049]
-Immunological detection;
After the transfer, the PVDF membrane was immersed in a blocking reagent (a reagent prepared by dissolving skim milk at a concentration of 5% in PBS containing 0.05% Tween-20) for 30 minutes at room temperature, and then diluted with a blocking reagent to 3000 times human aquaporin-. The mixture was reacted with 3 antibodies at 4 ° C for 24 hours. The human aquaporin-3 antibody was prepared by synthesizing a C-terminal peptide of the human aquaporin-3 amino acid sequence and preparing it from the serum of a rabbit immunized with the peptide, and the dilution factor was set in advance to obtain an appropriate detection signal. . Next, the PVDF membrane was washed by shaking in PBS containing 0.05% Tween-20, and then diluted with 2,000-fold anti-rabbit IgG antibody (manufactured by DAKO) in PBS containing 0.05% Tween-20 at room temperature for 45 minutes. Reacted. Finally, the PVDF membrane was washed by shaking in PBS containing 0.05% Tween-20, and then a signal was detected using SuperSignal (manufactured by PIERCE) according to the attached instructions. The results are shown in FIG. Tween-20 is a product name of Uniqema Americas.
[0050]
Compared with the sample-free group (Comparative Example 1), the freeze-dried Nosenhallen extract 0.001% (Example 4), the 0.01% -added group (Example 5), and the Nosenhallen 50% ethanol extraction solution 0.1% In the addition group (Example 6), a remarkable increase in detected signal intensity was observed. As is evident from the above, it was confirmed that the extract of the family Rubenaceae according to the present invention has an aquaporin synthesis promoting effect at an extremely low concentration.
[0051]
Hereinafter, formulation examples of the active oxygen scavenger, the hyaluronic acid synthesis promotion / decomposition inhibitor, and the aquaporin synthesis promoter of the present invention are shown.
[0052]
Formulation Examples 1-3 (skin cream)
A skin cream was prepared by blending the active oxygen scavenger, hyaluronic acid synthesis accelerating / degradation inhibitor, and aquaporin synthesis accelerating agent of Sample 1 or 2 with the compositions shown in Table 1 (Formulation Examples 1 to 3).
[0053]
(1) Composition
[Table 1]
Figure 2004168732
[0054]
(2) Preparation method
The components (A) and (B) were each heated and dissolved at 80 ° C., mixed, cooled with stirring, and cooled to 30 ° C. to prepare a skin cream.
[0055]
Formulation Examples 4-6 (Lotion)
The active oxygen scavenger, hyaluronic acid synthesis promotion / decomposition inhibitor, and aquaporin synthesis promoter of Sample 1 or 2 were blended in the composition shown in Table 2 to prepare lotions (Formulation Examples 4 to 6).
[0056]
(1) Composition
[Table 2]
Figure 2004168732
[0057]
(2) Preparation method
Each component was mixed and dissolved, and stirred to prepare a lotion.
[0058]
Formulation Examples 7-9 (Gel)
Gels were prepared by mixing the active oxygen scavenger, hyaluronic acid synthesis accelerator / decomposition inhibitor, and aquaporin synthesis accelerator of Sample 1 or 2 with the compositions shown in Table 3 (Formulation Examples 7 to 9).
[0059]
(1) Composition
[Table 3]
Figure 2004168732
[0060]
(2) Preparation method
The components (A) and (B) were each dissolved by heating at 60 ° C., mixed, cooled with stirring, and cooled to 30 ° C. to prepare a gel.
[0061]
Formulation Examples 10-12 (Gel)
The active oxygen scavenger, hyaluronic acid synthesis accelerating / degradation inhibitor, and aquaporin synthesis accelerating agent of Sample 1 or 2 were each blended with the compositions shown in Table 4 to prepare gels (Formulation Examples 10 to 12).
[0062]
(1) Composition
[Table 4]
Figure 2004168732
[0063]
(2) Preparation method
The components (A) and (B) were each dissolved by heating at 60 ° C., mixed, cooled with stirring, and cooled to 30 ° C. to prepare a gel.
[0064]
Formulation Examples 13 to 15 (lipophilic cream)
The active oxygen scavenger, hyaluronic acid synthesis accelerating / degradation inhibitor, and aquaporin synthesis accelerating agent of Sample 1 or 2 were blended in the composition shown in Table 5 to prepare lipophilic creams (Formulation Examples 13 to 15).
[0065]
(1) Composition
[Table 5]
Figure 2004168732
[0066]
(2) Preparation method
The components (A) and (B) were each heated and dissolved at 60 ° C., mixed, cooled with stirring, and cooled to 30 ° C. to prepare a lipophilic cream.
[0067]
Formulation Examples 16-18 (Sunscreen)
Sunscreens were prepared by blending the active oxygen scavenger, hyaluronic acid synthesis promotion / degradation inhibitor, and aquaporin synthesis promoter of Sample 1 or 2 with the compositions shown in Table 6 (Formulation Examples 16 to 18).
[0068]
(1) Composition
[Table 6]
Figure 2004168732
[0069]
(2) Preparation method
The components (A) and (B) were each heated and dissolved at 80 ° C., mixed, cooled with stirring, and cooled to 30 ° C. to prepare a sunscreen.
[0070]
Formulation Examples 19 to 21 (bath additives)
The active oxygen scavenger, hyaluronic acid synthesis accelerating / degradation inhibitor, and aquaporin synthesis accelerating agent of Sample 1 or 2 were blended with the compositions shown in Table 7 to prepare bathing agents (Formulation Examples 19 to 21).
[0071]
(1) Composition
[Table 7]
Figure 2004168732
[0072]
(2) Preparation method
The components (A) and (B) were each dissolved by heating at 60 ° C., mixed, cooled with stirring, and cooled to 30 ° C. to prepare a bath agent.
[0073]
Next, test examples for showing the effect will be described.
[0074]
Skin lotions and bath agents having the following compositions were prepared according to the respective preparation methods.
[0075]
Test Examples 1-3 and Comparative Example 2: Skin lotion
Ingredients Ingredients (%)
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
(Alcohol phase)
95% ethyl alcohol 15.0
Polyoxyethylene (60 mol) hydrogenated castor oil 2.0
Methyl paraoxybenzoate 0.05
Appropriate amount of fragrance
Sample (described in Table 8) Amount described in Table 8
(Aqueous phase)
Glycerin 5.0
Sodium citrate qs
Ion exchange water residue
(Total) 100.0
[0076]
Figure 2004168732
[0077]
・ Skin lotion preparation method
The aqueous phase and the alcohol phase are each uniformly dissolved, and the aqueous phase and the alcohol phase are mixed, dispersed by stirring, solubilized, and then filled in a container. When used, the contents are shaken and dispersed uniformly.
[0078]
A use test was performed using the skin lotion prepared above, and the effect of preventing skin aging and the effect of whitening were examined. The test method is as shown below.
[0079]
·Test method
The faces of 80 female subjects were divided into left and right sides, and one of the test examples 1 to 3 described above was applied to one side, and the skin lotion of Comparative Example 2 was applied twice or more daily to the other. A rating was given for each evaluation item according to the evaluation criteria described above, and the evaluation was made based on the total value of the ratings. The test subjects were divided into 20 groups and divided into three groups, and the skin lotions of Test Examples 1 to 3 were tested. Table 9 shows the results.
[0080]
Figure 2004168732
[0081]
[Table 9]
Evaluation item Test example 1 Test example 2 Test example 3
−−−−−−−−−−−−−−−−−−−−−−−−−−−
Preventing rough skin 25 20 41
Skin luster 27 21 43
Skin beam 31 28 45
Skin Brightness 29 22 39
Wrinkle improvement 24 19 37
[0082]
As is evident from Table 9, the skin lotion containing the freeze-dried Nosenharen extract according to the present invention as an active ingredient is effective in preventing rough skin, maintaining luster, firmness, brightness, and improving wrinkles. It became clear that it can be used as a skin cosmetic for preventing skin aging and for whitening.
[0083]
Test Example 4: Bath agent
Ingredients Ingredients (%)
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Sodium sulfate 85.0
Flavors and surfactants
Organic dye qs
Nosenhalen extract freeze-dried product 10.0
Sodium bicarbonate balance
(Total) 100.0
[0084]
・ Bath preparation method
Each component was mixed to prepare a bath agent. In addition, this bath agent is diluted about 3000 times at the time of use.
[0085]
The bath preparation was used by 20 subjects for bathing every day for three weeks. As a result, an effect was recognized in preventing rough skin, maintaining gloss, abrasion, brightness of the skin, and improving wrinkles. No abnormalities such as redness and drying caused by the skin lotion and bath agent according to the present invention were observed.
[0086]
【The invention's effect】
As described above, it is clear that an active oxygen scavenger, a hyaluronic acid synthesis promotion / decomposition inhibitor, and an aquaporin synthesis promoter that are effective for improving skin moisture retention, preventing skin roughness, and preventing aging can be provided.
[Brief description of the drawings]
BRIEF DESCRIPTION OF DRAWINGS FIG. 1 is a view showing the aquaporin synthesis-promoting effect of an extract of Nosenhalen on human normal epidermal keratinocytes.

Claims (6)

ノウゼンハレン科植物より得られる抽出物を含有することを特徴とする活性酸素消去剤。An active oxygen scavenger, comprising an extract obtained from a Nosenharenaceae plant. ノウゼンハレン科植物より得られる抽出物を含有することを特徴とするヒアルロン酸合成促進剤。A hyaluronic acid synthesis promoter comprising an extract obtained from a plant of the family Nosenharenaceae. ノウゼンハレン科植物より得られる抽出物を含有することを特徴とするヒアルロン酸分解抑制剤。A hyaluronic acid decomposition inhibitor comprising an extract obtained from a Nosenharenaceae plant. ノウゼンハレン科植物より得られる抽出物を含有することを特徴とするアクアポリン合成促進剤。An aquaporin synthesis promoter comprising an extract obtained from a plant of the family Nosenharenaceae. ノウゼンハレン科植物がノウゼンハレン属であることを特徴とする請求項1記載の活性酸素消去剤。2. The active oxygen scavenger according to claim 1, wherein the Russula plant is of the genus Russula. ノウゼンハレン科植物がノウゼンハレン(キンレンカ)であることを特徴とする請求項1記載の活性酸素消去剤。The active oxygen scavenger according to claim 1, wherein the Nosenharenaceae plant is Nosenharen (Nasturtium).
JP2002338871A 2002-11-22 2002-11-22 Active oxygen-scavenging agent, inhibitor for synthesis promotion/decomposition of hyaluronic acid, and aquaporin synthesis promotor Pending JP2004168732A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002338871A JP2004168732A (en) 2002-11-22 2002-11-22 Active oxygen-scavenging agent, inhibitor for synthesis promotion/decomposition of hyaluronic acid, and aquaporin synthesis promotor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002338871A JP2004168732A (en) 2002-11-22 2002-11-22 Active oxygen-scavenging agent, inhibitor for synthesis promotion/decomposition of hyaluronic acid, and aquaporin synthesis promotor

Publications (1)

Publication Number Publication Date
JP2004168732A true JP2004168732A (en) 2004-06-17

Family

ID=32701964

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002338871A Pending JP2004168732A (en) 2002-11-22 2002-11-22 Active oxygen-scavenging agent, inhibitor for synthesis promotion/decomposition of hyaluronic acid, and aquaporin synthesis promotor

Country Status (1)

Country Link
JP (1) JP2004168732A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006213681A (en) * 2005-02-07 2006-08-17 Kanebo Cosmetics Inc Wrinkle ameliorative agent
FR2893252A1 (en) * 2005-11-17 2007-05-18 Engelhard Lyon Sa VEGETABLE EXTRACTS STIMULATING HAS2
JP2007320920A (en) * 2006-06-01 2007-12-13 Niigata Univ Aquaporin 4 inhibitor
JP2009256271A (en) * 2008-04-18 2009-11-05 Maruzen Pharmaceut Co Ltd AQUAPORIN 3 mRNA EXPRESSION PROMOTOR AND SKIN MOISTURE RETENTION FUNCTION-IMPROVING AGENT
JP2011032191A (en) * 2009-07-31 2011-02-17 Kumamoto Univ Expression regulator of aquaporin 3
JP2011148732A (en) * 2010-01-21 2011-08-04 Maruzen Pharmaceut Co Ltd Aquaporin 3 production promoter
WO2012130771A1 (en) 2011-03-25 2012-10-04 Lipotec S.A. Peptides useful in the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions
JP2015199713A (en) * 2014-03-31 2015-11-12 日本メナード化粧品株式会社 External and internal preparation for skin containing nasturtium extract irradiated with light having specific wavelength band to cultivate
JP2022540460A (en) * 2019-07-09 2022-09-15 ソウル大学校産学協力団 Cosmetic composition containing graphene quantum dots as an active ingredient

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006213681A (en) * 2005-02-07 2006-08-17 Kanebo Cosmetics Inc Wrinkle ameliorative agent
FR2893252A1 (en) * 2005-11-17 2007-05-18 Engelhard Lyon Sa VEGETABLE EXTRACTS STIMULATING HAS2
JP2007320920A (en) * 2006-06-01 2007-12-13 Niigata Univ Aquaporin 4 inhibitor
JP2009256271A (en) * 2008-04-18 2009-11-05 Maruzen Pharmaceut Co Ltd AQUAPORIN 3 mRNA EXPRESSION PROMOTOR AND SKIN MOISTURE RETENTION FUNCTION-IMPROVING AGENT
JP2011032191A (en) * 2009-07-31 2011-02-17 Kumamoto Univ Expression regulator of aquaporin 3
JP2011148732A (en) * 2010-01-21 2011-08-04 Maruzen Pharmaceut Co Ltd Aquaporin 3 production promoter
WO2012130771A1 (en) 2011-03-25 2012-10-04 Lipotec S.A. Peptides useful in the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions
US9067967B2 (en) 2011-03-25 2015-06-30 Lipotec, S.A. Peptides useful in the treatment and care of the skin and mucous membranes and their use in cosmetic or pharmaceutical compositions
JP2015199713A (en) * 2014-03-31 2015-11-12 日本メナード化粧品株式会社 External and internal preparation for skin containing nasturtium extract irradiated with light having specific wavelength band to cultivate
JP2022540460A (en) * 2019-07-09 2022-09-15 ソウル大学校産学協力団 Cosmetic composition containing graphene quantum dots as an active ingredient
JP7490042B2 (en) 2019-07-09 2024-05-24 ソウル大学校産学協力団 Cosmetic composition containing graphene quantum dots as an active ingredient

Similar Documents

Publication Publication Date Title
US8709511B2 (en) External preparation composition for skin comprising ginseng flower or ginseng seed extracts
EP1638991B1 (en) Cosmetic or dermopharmaceutical composition for reducing the signs of cutaneous ageing
CN111053716B (en) Application of Fuzhuan tea extract in preparation of skin conditioning product
WO2010123102A1 (en) Collagen production promoter, anti-photoaging agent, moisture-retention improvement agent, and composite for use on skin
JP5683134B2 (en) Topical skin preparation
CN113164797B (en) Novel cosmetic and dermatological use of Cistus polyrhachis extract
JP2008201773A (en) External preparation for skin
JP2013502380A (en) Skin refining complex, use of said complex, cosmetic or pharmaceutical composition comprising said complex and method for its application
FR3059231A1 (en) COMPOSITION COMPRISING A TRUFFLE EXTRACT AND A DIHYDROCHALCONE
WO2019098352A1 (en) Cosmetic composition, screening method, and cosmetic method
JP5773111B2 (en) Composition for inhibiting skin pigmentation and use thereof
JP2001288032A (en) Active oxygen-eliminating agent and skin cosmetic for preventing aging
JP2004168732A (en) Active oxygen-scavenging agent, inhibitor for synthesis promotion/decomposition of hyaluronic acid, and aquaporin synthesis promotor
CN110870880A (en) Topical composition comprising pichia anomala and retinol
JP2008088075A (en) Profilaggrin/filaggrin production promoter, epidermal keratinocyte proliferation promoter, skin care preparation for normalizing epidermis/horny cell layer, profilaggrin/filaggrin production-promoting method and epidermal keratinocyte proliferation-promoting method
KR20180068909A (en) Skin external composition comprising germinated Camellia sinensis seed extract
EP3305370B1 (en) Algae autophagy activator
JP2005343882A (en) Hyaluronic acid production promoter, aquaporin synthesis promoter and composition of skin care preparation for external use
JP2006265120A (en) Collagen synthesis accelerator
KR101841118B1 (en) Composition for skin external application comprising extract of scenedesmus sp.
KR20110056884A (en) Composition comprising the mixture of map and msm for preventing baldness and improving hair growth
JP5117092B2 (en) Moisturizer, anti-aging agent, whitening agent, antioxidant, slimming agent, treatment agent, arginase activity promoter and external preparation for skin
KR101934564B1 (en) Skin external composition comprising germinated Camellia sinensis seed extract
JP2009256269A (en) Profilaggrin and/or filaggrin production accelerator
JP4861753B2 (en) Skin external composition

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041105

A625 Written request for application examination (by other person)

Free format text: JAPANESE INTERMEDIATE CODE: A625

Effective date: 20041105

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20041214

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20041227

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20041215

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20060110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070626